Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.41 CHF
−507.57 M CHF
7.51 B CHF
325.07 M
About BAUSCH HEALTH COMPANIES INC
Sector
CEO
Thomas J. Appio
Headquarters
Laval
Website
Founded
1994
FIGI
BBG006TLX225
Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, except for sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refers to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologic, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994, and is headquartered in Laval, Canada.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
BHC4634780
Bausch Health Companies Inc. 8.5% 31-JAN-2027Yield to maturity
20.20%
Maturity date
Jan 31, 2027
BHC4832634
Bausch Health Companies Inc. 7.0% 15-JAN-2028Yield to maturity
19.38%
Maturity date
Jan 15, 2028
BHC4986567
Bausch Health Companies Inc. 6.25% 15-FEB-2029Yield to maturity
17.59%
Maturity date
Feb 15, 2029
BHC4928364
Bausch Health Companies Inc. 5.25% 30-JAN-2030Yield to maturity
17.01%
Maturity date
Jan 30, 2030
BHC4927761
Bausch Health Companies Inc. 5.0% 30-JAN-2028Yield to maturity
16.90%
Maturity date
Jan 30, 2028
BHC5082241
Bausch Health Companies Inc. 5.0% 15-FEB-2029Yield to maturity
16.76%
Maturity date
Feb 15, 2029
BHC4832637
Bausch Health Companies Inc. 7.25% 30-MAY-2029Yield to maturity
16.35%
Maturity date
May 30, 2029
BHC5081958
Bausch Health Companies Inc. 5.25% 15-FEB-2031Yield to maturity
16.22%
Maturity date
Feb 15, 2031
Explore more bonds
Frequently Asked Questions
The current price of VRX is 21.44 CHF — it has increased by 3.68% in the past 24 hours. Watch BAUSCH HEALTH stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on SIX exchange BAUSCH HEALTH stocks are traded under the ticker VRX.
We've gathered analysts' opinions on BAUSCH HEALTH future price: according to them, VRX price has a max estimate of 10.42 CHF and a min estimate of 2.59 CHF. Watch VRX chart and read a more detailed BAUSCH HEALTH stock forecast: see what analysts think of BAUSCH HEALTH and suggest that you do with its stocks.
VRX stock is 4.62% volatile and has beta coefficient of 0.77. Track BAUSCH HEALTH stock price on the chart and check out the list of the most volatile stocks — is BAUSCH HEALTH there?
Today BAUSCH HEALTH has the market capitalization of 2.79 B, it has decreased by −2.00% over the last week.
Yes, you can track BAUSCH HEALTH financials in yearly and quarterly reports right on TradingView.
BAUSCH HEALTH is going to release the next earnings report on Feb 19, 2025. Keep track of upcoming events with our Earnings Calendar.
VRX earnings for the last quarter are 1.00 CHF per share, whereas the estimation was 0.89 CHF resulting in a 12.36% surprise. The estimated earnings for the next quarter are 0.99 CHF per share. See more details about BAUSCH HEALTH earnings.
BAUSCH HEALTH revenue for the last quarter amounts to 2.19 B CHF, despite the estimated figure of 2.10 B CHF. In the next quarter, revenue is expected to reach 2.22 B CHF.
VRX net income for the last quarter is −72.61 M CHF, while the quarter before that showed 8.99 M CHF of net income which accounts for −907.82% change. Track more BAUSCH HEALTH financial stats to get the full picture.
No, VRX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 17, 2024, the company has 20.27 K employees. See our rating of the largest employees — is BAUSCH HEALTH on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. BAUSCH HEALTH EBITDA is 2.61 B CHF, and current EBITDA margin is 32.71%. See more stats in BAUSCH HEALTH financial statements.
Like other stocks, VRX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade BAUSCH HEALTH stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So BAUSCH HEALTH technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating BAUSCH HEALTH stock shows the sell signal. See more of BAUSCH HEALTH technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.